Form **8937**(December 2011) Department of the Treasury Internal Revenue Service

Report of Organizational Actions Affecting Basis of Securities

► See separate instructions.

OMB No. 1545-2224

Part I Reporting Issuer				
1 Issuer's name		2 Issuer's employer identification number (EIN)		
Enzon Pharmaceuticals, Inc.	22-2372868			
3 Name of contact for additional information	4 Telephone No. of contact	5 Email address of contact		
Richard Feinstein	516-526-1709	rlfeinsteincpa@gmail.com		
6 Number and street (or P.O. box if mail is not delivered to street address) of contact		7 City, town, or post office, state, and Zip code of contact		
20 Kingsbridge Road		Piscataway, NJ 08854		
8 Date of action				
4/00/0045				
1/28/2015 10 CUSIP number	Distribution of cash 12 Ticker symbol	13 Account number(s)		
11 Serial Humber(s)	12 Ticker Symbol	13 Account number(s)		
N/A N/A	ENZN	N/A (4.4.1)		
	h additional statements if needed. See			
		e against which shareholders' ownership is measured for		
		h distribution of \$0.10 per share for a total of		
\$4,417,445. to its shareholders of record on 3	January 12, 2015.			
	The American State of the Communication of the Comm			
•		ty in the hands of a U.S. taxpayer as an adjustment per		
		\$0.04 per share is estimated to be a taxable		
dividend (with no effect on basis). To the external		an \$0.06 per share, the excess of \$0.06 over		
the basis in that share is recognized as a cap	ital gain.			
16 Describe the calculation of the change in b	asis and the data that supports the calcula	ation, such as the market values of securities and the		
•	• •	made by a corporation, it is treated as a taxable		
•		of that corporation at the date of the distribution or, in		
		r to determine what portion of this cash distribution		
		Pharmaceuticals, Inc. completed a computation of E&P		
		led December 31, 2015. According to this computation,		
Enzon Pharmaceuticals, Inc. had approximately \$0.04 of E&P per outstanding share of stock. As a result, the distribution of \$0.10 per				
share resulted in a dividend of \$0.04 per share				

Form 8937	(Rev. 12-2011	Enzon Pharmaceuticals, Inc.	22-2372868 Page 2	
Part II	Orgar	nizational Action (continued)		
		able Internal Revenue Code section(s) and subsection(s) upon which the tax treatment is be	ased >	
		end defined erty defined		
		tributions of property		
		on earnings and profits		
	······································			
				
18 Ca	in any result	ing loss be recognized? ► This distribution would not create a loss.		
	····			
			•	
		·		
19 Pro	nvide anv ot	her information necessary to implement the adjustment, such as the reportable tax year 🕨	The adjustment to basis would be	
		n the tax year of the shareholder during which the distribution was received.		
			AND A CONTRACTOR OF THE CONTRA	

M			Andrew	
	T 1 1 - d	ties of perjury, I declare that I have examined this return, including accompanying schedules and statement	and to the heat of my knowledge and	
	'	ties of perjury, I declare that I have examined this return, including accompanying scriedules and statement ue, correct, and complete. Declaration of preparer (other than officer) is based on all information of which pr		
Sign	Delici, it is the	ac, correct, and complete. Declaration of prepared (other than others) to back on all information of which pr	oparor has any knowledge.	
Here	Signature	Date ►		
•	Print your na	ame ► Title ►		
Paid	Print/Ty	pe preparer's name Preparer's signature Date	Check if PTIN	
Prepare		as M Prendergast CPA	//6 self-employed P00535729	
Use On	- 1		Firm's EIN ► 39-0859910	
		ddress ► 1650 Market Street, Suite 4500, Philadelphia, PA 19103	Phone no. (215) 972-0701	
Send Form 8937 (including accompanying statements) to: Department of the Treasury, Internal Revenue Service, Ogden, UT 84201-0054				